Market Overview

Hard To See If Regeneron's Eylea Combo Study Failure Reads Through To Ophthotech's Fovista

Share:
Hard To See If Regeneron's Eylea Combo Study Failure Reads Through To Ophthotech's Fovista

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced that the Phase 2 CAPELLA trial of Eylea co-formulated with an anti-PDGFR-beta antibody, runicumab, did not meet the primary endpoint.

Baird’s Brian P. Skorney maintained a Neutral rating on the company, with a price target of $448. He mentioned that the co-formulation arms performed worse than Eylea alone.

“While this is a high-profile failure for Regeneron, it implies higher risk of failure for potentially competitor, Fovista, but also makes Fovista's more dangerous to Eylea's market share, should it succeed,” the analyst stated.

Eylea monotherapy performed better than the co-formulation arms on both the primary and the secondary endpoints, including the anatomic endpoints of reduced retinal thickness and resolution of sub-retinal hyper-reflective material.

Related Link: Here's Why Ophthotech Is Trading Down On Regeneron's News

What It Means For Fovista

Ophthotech Corp’s (NASDAQ: OPHT) Fovista is currently in Phase 3 trials in combination with Avastin and Lucentis.

“If successful, we would expect to see a shift in market share away from Eylea towards Lucentis and Avastin due to the combination potential with Fovista,” Skorney said.

However, the failure of Regeneron’s own Eylea/anti-PDGFR combination might indicate that the Fovista results could also be negative.p

“Even if Fovista fails in Phase 3, we think it is important in the long-run that Regeneron has a next-generation co-formulation for Eylea to combat against biosimilar Lucentis erosion,” the analyst added.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for REGN

DateFirmActionFromTo
Nov 2020Morgan StanleyMaintainsEqual-Weight
Nov 2020Credit SuisseMaintainsOutperform
Nov 2020SVB LeerinkMaintainsOutperform

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

 

Related Articles (REGN + OPHT)

View Comments and Join the Discussion!

Posted-In: Baird Brian P. Skorney EYLEAAnalyst Color Long Ideas Reiteration Analyst Ratings Trading Ideas Best of Benzinga

Latest Ratings

StockFirmActionPT
PMTB of A SecuritiesMaintains18.5
IVRB of A SecuritiesMaintains3.0
EFCB of A SecuritiesMaintains15.5
NYMTB of A SecuritiesMaintains3.5
NLYB of A SecuritiesMaintains8.5
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com